000892695 001__ 892695
000892695 005__ 20210623133504.0
000892695 0247_ $$2doi$$a10.1021/acsmedchemlett.0c00658
000892695 0247_ $$2Handle$$a2128/27820
000892695 0247_ $$2pmid$$a34055220
000892695 0247_ $$2WOS$$aWOS:000651790900010
000892695 037__ $$aFZJ-2021-02273
000892695 082__ $$a610
000892695 1001_ $$0P:(DE-Juel1)173964$$aWillmann, Michael$$b0$$ufzj
000892695 245__ $$aRadiosynthesis and Biological Evaluation of [18F]R91150, a Selective 5-HT2A Receptor Antagonist for PET-Imaging
000892695 260__ $$aWashington, DC$$bACS$$c2021
000892695 3367_ $$2DRIVER$$aarticle
000892695 3367_ $$2DataCite$$aOutput Types/Journal article
000892695 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1621516261_5765
000892695 3367_ $$2BibTeX$$aARTICLE
000892695 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000892695 3367_ $$00$$2EndNote$$aJournal Article
000892695 520__ $$aSerotonergic 5-HT2A receptors in cortical and forebrain regions are an important substrate for the neuromodulatory actions of serotonin in the brain. They have been implicated in the etiology of many neuropsychiatric disorders and serve as a target for antipsychotic, antidepressant, and anxiolytic drugs. Positron emission tomography imaging using suitable radioligands can be applied for in vivo quantification of receptor densities and receptor occupancy for therapy evaluation. Recently, the radiosynthesis of the selective 5-HT2AR antagonist [18F]R91150 was reported. However, the six-step radiosynthesis is cumbersome and time-consuming with low radiochemical yields (RCYs) of <5%. In this work, [18F]R91150 was prepared using late-stage Cu-mediated radiofluorination to simplify its synthesis. The detailed protocol enabled us to obtain RCYs of 14 ± 1%, and the total synthesis time was reduced to 60 min. In addition, autoradiographic studies with [18F]R91150 in rat brain slices revealed the typical uptake pattern of 5-HT2A receptor ligands.
000892695 536__ $$0G:(DE-HGF)POF4-525$$a525 - Decoding Brain Organization and Dysfunction (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000892695 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000892695 7001_ $$0P:(DE-HGF)0$$aHegger, Julian$$b1
000892695 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, Bernd$$b2$$eCorresponding author
000892695 7001_ $$0P:(DE-Juel1)131818$$aErmert, Johannes$$b3
000892695 773__ $$0PERI:(DE-600)2532386-6$$a10.1021/acsmedchemlett.0c00658$$gVol. 12, no. 5, p. 738 - 744$$n5$$p738 - 744$$tACS medicinal chemistry letters$$v12$$x1948-5875$$y2021
000892695 8564_ $$uhttps://juser.fz-juelich.de/record/892695/files/18FR91150%20Final%20Version.pdf$$yPublished on 2021-04-01. Available in OpenAccess from 2022-04-01.
000892695 8564_ $$uhttps://juser.fz-juelich.de/record/892695/files/acsmedchemlett.0c00658%281%29.pdf$$yRestricted
000892695 909CO $$ooai:juser.fz-juelich.de:892695$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000892695 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)173964$$aForschungszentrum Jülich$$b0$$kFZJ
000892695 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-HGF)0$$aForschungszentrum Jülich$$b1$$kFZJ
000892695 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b2$$kFZJ
000892695 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131818$$aForschungszentrum Jülich$$b3$$kFZJ
000892695 9130_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000892695 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000892695 9141_ $$y2021
000892695 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-28
000892695 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000892695 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-28
000892695 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000892695 915__ $$0StatID:(DE-HGF)0530$$2StatID$$aEmbargoed OpenAccess
000892695 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bACS MED CHEM LETT : 2019$$d2021-01-28
000892695 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-01-28
000892695 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000892695 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-28
000892695 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-01-28
000892695 915__ $$0StatID:(DE-HGF)1200$$2StatID$$aDBCoverage$$bChemical Reactions$$d2021-01-28
000892695 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-28
000892695 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-01-28
000892695 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-28
000892695 920__ $$lyes
000892695 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
000892695 980__ $$ajournal
000892695 980__ $$aVDB
000892695 980__ $$aUNRESTRICTED
000892695 980__ $$aI:(DE-Juel1)INM-5-20090406
000892695 9801_ $$aFullTexts